Blood Cross-Matching: Pre-Transfusion Compatibility Testing, Antibody Screening and Emergency Release
Study level: Clinical medicine, emergency medicine and pathology | Topic: Hematology and transfusion medicine
Core concept: Cross-matching is the final compatibility check between a recipient and a specific donor unit. It complements ABO/Rh typing and antibody screening; it does not replace correct patient identification, historical antibody review or bedside verification.
Learning objectives
- Explain the difference between type-and-screen, antibody screen, cross-match, DAT and IAT.
- Describe serologic and electronic cross-match workflows.
- Recognise clinically significant antibodies and incompatible results.
- Manage emergency-release blood while testing is incomplete.
- Prevent wrong-blood-in-tube and wrong-patient errors.
1. The pre-transfusion testing pathway
- Clinical request: specify component, urgency, indication, special processing and anticipated number of units.
- Correct specimen: collect and label a patient sample at bedside using two identifiers; include transfusion/pregnancy history.
- ABO/Rh(D) typing: test patient RBC antigens and confirm with plasma reverse grouping.
- Antibody screen: incubate patient plasma with reagent group O screening cells expressing common antigens.
- Antibody identification: if screen is positive, test a panel to determine specificity and clinical significance.
- Donor-unit selection: choose ABO/Rh-compatible, antigen-negative and specially processed units.
- Cross-match: test recipient plasma against donor RBCs, electronically or serologically according to policy.
- Bedside check: independently verify patient, unit, group, compatibility, expiry and special requirements immediately before administration.
2. Key tests and terminology
| Test/term | What it does | Clinical meaning |
|---|---|---|
| ABO/Rh typing | Identifies RBC antigens using forward/reverse grouping and anti-D testing. | Prevents major ABO/Rh incompatibility. |
| Antibody screen (IAT) | Detects unexpected IgG antibodies in patient plasma using reagent screening cells. | Predicts delayed/acute haemolysis and guides antigen-negative selection. |
| Antibody identification panel | Maps reaction pattern against cells with known antigen profiles. | Determines whether anti-K, anti-E, anti-Jka or another antibody is present. |
| Major cross-match | Recipient plasma + donor RBCs. | Detects antibodies that would attack transfused RBCs; the essential final compatibility test. |
| Minor cross-match | Donor plasma + recipient RBCs. | Historically used with whole blood; less relevant for modern packed RBCs but plasma compatibility remains important. |
| Electronic cross-match | Validated computer check using current ABO/Rh and negative antibody screen/history. | Fast and safe only when all system criteria are met. |
| Immediate-spin cross-match | Rapid ABO incompatibility check at room temperature. | Insufficient alone if clinically significant antibodies are present. |
| AHG/antiglobulin cross-match | Incubation with antihuman globulin detects IgG-mediated reactions. | Required when antibody screen/history is positive or policy demands it. |
| DAT (direct antiglobulin test) | Detects IgG/complement already coating patient RBCs in vivo. | Useful in autoimmune/drug haemolysis and transfusion reactions. |
| IAT (indirect antiglobulin test) | Detects antibodies in plasma that can bind reagent/donor RBCs in vitro. | Used for antibody screening and compatibility testing. |
3. Clinically significant antibodies
- Most clinically important alloantibodies are IgG, react at 37°C/AHG phase and can cause extravascular haemolysis or HDFN.
- Common significant systems include Rh (D, C, c, E, e), Kell, Kidd, Duffy and selected MNS antibodies.
- Anti-A and anti-B are usually IgM/complement-activating and cause severe immediate intravascular haemolysis when incompatible.
- Some antibodies become undetectable over time; a historical antibody remains clinically relevant even if the current screen is negative.
- Cold-reactive antibodies may be clinically insignificant at body temperature, but laboratory interpretation is essential because some complement-reactive antibodies are dangerous.
4. What an incompatible cross-match means
| Pattern | Possible explanation | Action |
|---|---|---|
| ABO mismatch | Wrong group, sample error, reagent issue or major clerical problem. | Stop, repeat patient typing and investigate identity; do not release the unit. |
| Positive screen + incompatible donor unit | Donor expresses the target antigen. | Select antigen-negative unit and perform antiglobulin cross-match. |
| Positive screen + apparently compatible panel | Autoantibody, low-incidence antigen, dosage effect or multiple antibodies. | Reference laboratory, adsorption/genotyping and specialist consultation. |
| Panagglutination | Warm autoantibody, cold interference, drug antibody or contamination. | DAT, autocontrol, pre-warm technique and specialised work-up. |
| Recent transfusion/mixed field | Two RBC populations, donor cells, stem-cell transplant or weak subgroup. | Review history, genotype where useful and avoid relying on phenotype alone. |
5. Specimen collection and validity
- Use two identifiers and label the tube at the bedside immediately after collection.
- Record date/time, collector identity, pregnancy/transfusion history and current antibody status.
- Many services limit a pre-transfusion sample to about 72–96 hours when the patient has been recently transfused or pregnant because new antibodies can develop; local policy governs expiry.
- Reject haemolysed, clotted, unlabeled, mislabeled or insufficient samples; redraw rather than guessing.
- Do not draw from a line containing blood or IV medication unless the laboratory has an approved technique.
6. Electronic and serologic cross-match
6.1 Electronic cross-match
A validated system checks that the patient has a compatible historical and current ABO/Rh result, a negative antibody screen and no unresolved clinically significant antibody. It reduces delays and manual error but fails if records are incomplete, the sample is invalid or the patient has a current/historical antibody.
6.2 Serologic cross-match
Recipient plasma is incubated with donor RBCs and tested through the required phases, including antihuman globulin when IgG antibodies are possible. A visible or instrument-detected reaction indicates incompatibility until resolved.
6.3 Cross-match is not a bedside substitute
A compatible laboratory result cannot protect a patient if the wrong unit is attached to the wrong patient. Bedside identity checks must be repeated immediately before transfusion.
7. Emergency-release blood
- In exsanguinating haemorrhage, do not delay life-saving RBCs for full testing.
- Obtain a correctly labeled pre-transfusion sample before release whenever feasible.
- Blood bank may issue uncrossmatched group O or group-specific RBCs under emergency policy; select Rh strategy according to age, sex, pregnancy potential, inventory and local guidance.
- Continue ABO/Rh typing, antibody screen and cross-match in parallel.
- Switch to fully compatible antigen-negative units as soon as available, and document the emergency rationale.
Emergency release increases risk but is safer than allowing a patient to exsanguinate. The decision should be communicated clearly and recorded.
8. Special scenarios
- Warm autoimmune haemolytic anaemia: panreactive autoantibody may make all units appear incompatible; transfusion is based on clinical need, after excluding alloantibodies with specialist methods.
- Sickle cell disease/thalassaemia: use extended phenotype/genotype matching and historical antibody review to reduce alloimmunisation.
- Pregnancy: screen for anti-D, anti-c, anti-K and other antibodies; coordinate maternal and fetal monitoring.
- Stem-cell transplant: ABO mismatch does not always preclude transplant, but component selection is specialised and may change over engraftment.
- Massive transfusion: emergency blood may precede complete testing; maintain traceability and update compatibility as samples become available.
9. Quality and error prevention
- Use independent double-checks or barcode scanning for patient and unit.
- Compare current and historical groups; unexplained changes are a safety stop.
- Never accept verbal group history as the sole basis for routine transfusion.
- Record antibodies permanently in the patient’s record and provide the patient an alert card where available.
- Report near misses; a wrong-blood-in-tube event is a system warning even if no unit was transfused.
10. Clinical cases
Case 1: positive antibody screen
A patient with prior pregnancy has a positive screen and an anti-K pattern. Select K-negative donor units and perform a full antiglobulin cross-match; do not use “O negative” alone as a solution.
Case 2: emergency release
A patient with ruptured ectopic pregnancy is shocked and needs immediate RBCs. Draw the sample first if possible, release emergency-compatible blood, activate haemorrhage protocol and complete testing in parallel.
Case 3: incompatible unit in warm autoantibody
A patient with autoimmune haemolytic anaemia has panagglutination. Involve the reference laboratory to exclude underlying alloantibodies; if clinically unstable, transfuse the safest available matched units under haematology/blood-bank direction rather than withholding life-saving support.
11. Quick self-test
- What is tested in the major cross-match?
- How does DAT differ from IAT?
- When is electronic cross-match acceptable?
- Why does a historical antibody remain important?
- What should happen when the sample is mislabeled?
- Why must cross-match be performed in parallel with emergency resuscitation?
Answers
- Recipient plasma against donor RBCs.
- DAT detects antibody/complement already coating patient RBCs in vivo; IAT detects plasma antibodies in vitro.
- When validated criteria are met: current and historical ABO/Rh are compatible, antibody screen is negative and no significant antibody is unresolved.
- Antibody levels can fall below detection but rise rapidly on re-exposure, causing delayed haemolysis.
- Reject and redraw a correctly identified sample; never guess or relabel retrospectively.
- Testing reduces incompatibility risk, but delaying blood in exsanguination can be fatal; both processes must proceed together.
Key take-home points
- Cross-match is the final laboratory compatibility check, not the entire transfusion-safety process.
- Antibody screening and historical records protect against non-ABO haemolysis and HDFN.
- Electronic cross-match is fast but only safe when strict prerequisites are met.
- Emergency blood is issued under protocol while testing continues; obtain a sample before transfusion whenever possible.
- Identity errors remain preventable—bedside verification is mandatory.
